Immune-Mediated Colitis — Tofacitinib for the Treatment of Refractory Immune-related Colitis From Checkpoint Inhibitor Therapy- TRICK Study
Citation(s)
An Open-label Study of Tofacitinib for the Treatment of Refractory Immune-related Colitis From checKpoint Inhibitor Therapy (TRICK)